Joel R Rivera Concepcion

Conference Journal of Clinical Oncology · June 1, 2026 2619Background: Immunotherapy resistance remains a significant unmet clinical need for most non-small cell lung cancer (NSCLC) patients. PCSK9 was shown in preclinical models to mediate cancer immunotherapy resistance and may serve as a novel immuno-inhibi ... Full text Cite

Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.

Conference Journal of Clinical Oncology · June 2025 TPS8118Background: The addition of immune checkpoint blockade to neoadjuvant and adjuvant therapy is now standard of care in ... Full text Cite

A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms

Journal article Current Problems in Cancer: Case Reports · March 2024 Full text Cite

Subtyping of Small Cell Carcinoma Remains Unchanged After Recurrence, Supported by RNA Expression and Highly Concordant IHC Approaches

Conference LABORATORY INVESTIGATION · March 2024 Link to item Cite

Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment.

Journal article JTO Clin Res Rep · September 2023 INTRODUCTION: SCLC is an aggressive malignancy with poor outcome. Most patients have disease recurrence despite treatments with multiple modalities. Subtyping of SCLC has been proposed recently, and novel agents targeting specific subtypes are actively bei ... Full text Link to item Cite